Coya Therapeutics (COYA) Announces $26.5 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Coya Therapeutics (COYA) and Dr. Reddy’s Laboratories Enter into Exclusive Collaboration for Development and Commercialization of COYA 302
December 6, 2023 7:01 AM ESTDr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys), and Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya), today announced that they have entered into a development and license agreement (the Agreement) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Under the terms of the Agreement, Coya has granted Dr. Reddys an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination... More
Coya Therapeutics (COYA) Halted, News Pending
December 6, 2023 6:55 AM ESTCoya Therapeutics (NASDAQ: COYA) Halted, News Pending
